دورية أكاديمية
أعرض في EDS

Implementation of ultra-hypofractionated radiotherapy schedules for breast cancer during the COVID-19 pandemic in the Netherlands.

التفاصيل البيبلوغرافية
العنوان: Implementation of ultra-hypofractionated radiotherapy schedules for breast cancer during the COVID-19 pandemic in the Netherlands.
المؤلفون: Eijkelboom AH; Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Drienerlolaan 5, 7522 NB, Enschede, the Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Boven Clarenburg 2, 3511 CV, Utrecht, the Netherlands., Stam MR; Radiotherapiegroep, Wagnerlaan 47, 6815 AD Arnhem, the Netherlands., van den Bongard DHJG; Department of Radiation Oncology, Amsterdam UMC, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands., Sattler MGA; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands., Bantema-Joppe EJ; Department of Radiation Oncology, Radiotherapy Institute Friesland, Borniastraat 36, 8934 AD Leeuwarden, the Netherlands., Siesling S; Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Drienerlolaan 5, 7522 NB, Enschede, the Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Boven Clarenburg 2, 3511 CV, Utrecht, the Netherlands., van Maaren MC; Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Drienerlolaan 5, 7522 NB, Enschede, the Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Boven Clarenburg 2, 3511 CV, Utrecht, the Netherlands.
المصدر: Clinical and translational radiation oncology [Clin Transl Radiat Oncol] 2024 Jun 14; Vol. 47, pp. 100807. Date of Electronic Publication: 2024 Jun 14 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Ireland Ltd. on behalf of European Society for Radiotherapy and Oncology Country of Publication: Ireland NLM ID: 101713416 Publication Model: eCollection Cited Medium: Internet ISSN: 2405-6308 (Electronic) Linking ISSN: 24056308 NLM ISO Abbreviation: Clin Transl Radiat Oncol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Shannon] : Elsevier Ireland Ltd. on behalf of European Society for Radiotherapy and Oncology, [2016]-
مستخلص: Background and Purpose: The COVID-19 pandemic resulted in an accelerated recommendation to use five-fraction radiotherapy schedules, according to the FAST- and FAST-Forward trial. In this study, trends in the use of different radiotherapy schedules in the Netherlands were studied, as well as the likelihood of receiving five fractions.
Materials and Methods: Data from the NABON Breast Cancer Audit-Radiotherapy and Netherlands Cancer Registry was used. Women receiving radiotherapy for their primary invasive breast cancer or DCIS between 01-01-2020 and 31-12-2021 were included. Logistic regression was used to investigate the association between patient-, tumour-, treatment-, and radiotherapy institution-related characteristics and the likelihood of receiving five fractions in tumours meeting the FAST and FAST-Forward criteria.
Results: Detailed information about radiotherapy treatment was available for 9,392 tumours. Shortly after the start of the COVID-19 pandemic, i.e. April 2020, 19% of the tumours being treated with radiotherapy received five fractions of 5.2 or 5.7 Gray (Gy). While only 3% of the tumours received five fractions in March 2020. The usage of five fractions increased to 26% in December 2021. Partial breast irradiation, compared to whole breast irradiation, was significantly associated with the administration of five fractions, as well as radiotherapy delivered in an academic radiotherapy institution compared to an independent institution.
Conclusion: The start of the COVID-19 pandemic was associated with the early use of ultra-hypofractionated radiotherapy schedules. After publication of the trials, and mainly after the recommendation by the national radiotherapy society, the implementation further increased. These schedules were not yet used in all patients meeting the eligibility criteria for the FAST- or FAST-Forward trial.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2024 The Author(s).)
References: Clin Oncol (R Coll Radiol). 2021 Jul;33(7):430-439. (PMID: 34023185)
Lancet. 2011 Nov 12;378(9804):1707-16. (PMID: 22019144)
J Clin Oncol. 2020 Oct 1;38(28):3261-3272. (PMID: 32663119)
Lancet. 2020 May 23;395(10237):1613-1626. (PMID: 32580883)
Clin Oncol (R Coll Radiol). 2022 Sep;34(9):e400-e409. (PMID: 35691761)
J Natl Compr Canc Netw. 2022 Jun;20(6):691-722. (PMID: 35714673)
Breast. 2021 Aug;58:72-79. (PMID: 33933925)
Lancet Oncol. 2013 Oct;14(11):1086-1094. (PMID: 24055415)
Lancet. 2014 Jun 21;383(9935):2127-35. (PMID: 24656685)
Radiat Oncol. 2022 Apr 12;17(1):73. (PMID: 35413924)
Radiother Oncol. 2016 Jul;120(1):114-8. (PMID: 27046390)
Acta Oncol. 2023 Dec;62(12):1791-1797. (PMID: 37824092)
JAMA Oncol. 2015 Oct;1(7):931-41. (PMID: 26247543)
Clin Oncol (R Coll Radiol). 2020 May;32(5):279-281. (PMID: 32241520)
JCO Glob Oncol. 2022 Jul;8:e2100365. (PMID: 35802835)
Lancet Oncol. 2022 Jan;23(1):e21-e31. (PMID: 34973228)
Radiother Oncol. 2010 Mar;94(3):264-73. (PMID: 20181402)
Lancet. 2008 Mar 29;371(9618):1098-107. (PMID: 18355913)
Lancet Oncol. 2008 Apr;9(4):331-41. (PMID: 18356109)
N Engl J Med. 2010 Feb 11;362(6):513-20. (PMID: 20147717)
J Natl Cancer Inst. 2017 Nov 1;109(11):. (PMID: 29059428)
J Clin Oncol. 2020 Dec 10;38(35):4175-4183. (PMID: 32840419)
Radiother Oncol. 2018 Jan;126(1):155-162. (PMID: 29153463)
Breast Cancer Res Treat. 2015 Aug;152(3):627-36. (PMID: 26162567)
فهرسة مساهمة: Keywords: Breast cancer; Clinical guideline; Radiotherapy
تواريخ الأحداث: Date Created: 20240709 Latest Revision: 20240710
رمز التحديث: 20240710
مُعرف محوري في PubMed: PMC11228630
DOI: 10.1016/j.ctro.2024.100807
PMID: 38979479
قاعدة البيانات: MEDLINE
الوصف
تدمد:2405-6308
DOI:10.1016/j.ctro.2024.100807